Plexium
Discovers targeted monovalent protein degraders using high-throughput cellular screening.
What they do
Plexium develops targeted protein degradation therapeutics using a high-throughput cell-based screening platform. The technology allows pharmaceutical researchers to identify small molecules, such as monovalent degraders and molecular glues, that selectively target and destroy disease-causing proteins.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein degradation
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- San Diego, USA
- Region
- North America
- Founded
- 2018
- Total funding
- $165M raised
Notable investors: BVF Partners, TCG Crossover, Amgen Ventures, Vertex Ventures.